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and is superior to Gleason score as a predictor
of biochemical recurrence after radical
prostatectomy
Jon Slezak1†, Matthew Truong1†, Wei Huang2 and David Jarrard3*Abstract
Background: Aberrant chromatin structure in cancer cells results from altered proteins involved in its packaging.
Heterochromatin protein 1 gamma (HP1γ) is a non-histone heterochromatic protein that functions to maintain
chromatin stability and is important in embryonic development. Given an interest in the role developmental genes
play in cancer, we investigated HP1γ expression in prostate cancer (PCa) and its prognostic associations.
Methods: Tissue microarrays consisting of benign (N = 96), localized cancer (N = 146), metastatic PCa (N = 44), and
HGPIN (N = 50) were immunoflourescently stained for HP1γ and Ki-67. Using a novel, automated quantitative
imaging system, VECTRA™, epithelial staining in both the nucleus and cytoplasm was quantified and compared
against clinicopathologic variables.
Results: HP1γ is significantly elevated in HGPIN (80%), localized PCa (76%), and metastatic PCa (98%) compared to
benign tissues from both the nuclear and cytoplasmic compartments (P < 0.0001). Increased nuclear and total HP1γ
expression was associated with Gleason score (P = 0.02 and P = 0.04 respectively). Given known binding to the
C-terminus of Ki-67, a co-expression analysis was performed that revealed a correlation between nuclear and
cytoplasmic HP1γ and Ki-67 (Pearson Coefficient 0.321 and 0.562 respectively, P < 0.0001). Cox survival analysis
demonstrated that cytoplasmic HP1γ expression was an independent prognostic marker and out-performed
pathological Gleason score for predicting PSA-recurrence after radical prostatectomy.
Conclusions: In this first detailed analysis of HP1γ expression in cancer, VECTRA™ demonstrates compartmentalized
and total HP1γ protein expression is increased in PCa and that expression correlates with clinical outcomes better
than Gleason score. Given the critical role HP1γ plays in chromatin organization and gene expression, it represents
a novel prognostic and therapeutic target.
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Prostate cancer (PCa) is the second most common cancer
in men and will account for approximately 28,170 deaths
in 2012 [1]. The behavior of some cancers can be variable
despite Gleason score and other clinicopathologic factors.
Recent efforts have focused on developing biomarkers that
provide clinicians with the improved ability to identify* Correspondence: Jarrard@urology.wisc.edu
†Equal contributors
3Department of Urology, University of Wisconsin-Madison, Madison, WI
53705, USA
Full list of author information is available at the end of the article
© 2013 Slezak et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orclinically significant cancers and aid in treatment deci-
sions. Genes important in embryogenesis frequently play a
role in cancer [2]. One such gene, heterochromatin pro-
tein 1 gamma (HP1γ), is critically involved in chromatin
packaging [3] and demonstrates altered expression during
development and cell differentiation [4-6].
HP1γ, along with HP1α and HP1β, belong to a family
of heterochromatin proteins with stabilizing functions.
The structure of HP1 contains an evolutionarily con-
served chromodomain that binds to a methylated lysine
on histone H3 (H3K9me) [7]. This binding epigeneticallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HP1 stabilizes telomeric and centromeric heterochromatin
structure and facilitates DNA repair after disruption or
damage [9,10]. This chromatin repair function is import-
ant to maintain information encoded in the epigenetic
histone code [9]. The HP1 isoforms appear to have differ-
ential functions. HP1γ has the ability to regulate both het-
erochromatin and euchromatin structure, while the other
isoforms are localized only on heterochromatin.
Decreased expression of HP1γ occurs during cell differ-
entiation which is unique to this isoform compared to
HP1α and β [6]. In differentiated human tissues levels of
HP1γ are generally not detectable [11]. Silencing of HP1γ
has functional consequences. In selected cancer cell lines,
growth is inhibited. In a recent screen of cancer tissues,
HP1γ protein appeared to be overexpressed in samples of
lung, breast, colon and esophageal [5]. Although decreased
levels of its isoform HP1α were found in metastatic breast
cancer compared to localized [12], HP1γ has not been pre-
viously evaluated as a marker for cancer progression.
Herein, we identify a novel overexpression of HP1γ
in PCa tissues using a tissue microarray (TMA) and
VECTRA™ image acquisition technology. This quantitative
tool permits localization of expression to nuclear versus
cytoplasmic compartments. We report that nuclear and
cytoplasmic HP1γ is progressively increased in HGPIN,
PCa, and metastatic PCa cores compared to benign tissue.
Furthermore, increased HP1γ is correlated with Ki-67, a
protein known to complex with other heterochromatin
family proteins [13]. Finally, we report a novel prognostic
role for cytoplasmic HP1γ in independently predicting
PSA recurrence following prostatectomy. The use of high-
throughput imaging technologies such as VECTRA allows
for quantitative compartmentalization of marker expres-




The University of Wisconsin Institutional Review Board
(IRB) provides ethical insight to clinical projects and re-
views all human research protocols in accordance with fed-
eral regulations, state laws, and local and University
policies. FFPE-patient tissues were obtained from the Uni-
versity of Wisconsin Department of Pathology and Labora-
tory Medicine under IRB approval. A tissue microarray
was constructed using tissues from 64 PCa patients (mean
age, 62.8 years) collected from 1995 to 2006. The mean
follow-up period for this cohort was 9.6 years. The TMA
consists of 336 duplicate cores from different disease
groups: 43 localized PCa (pT2), 30 aggressive PCa (pT3
and 4), 21 metastatic PCa, 23 high grade intraepithelial
neoplasia (HGPIN) (tissue from HGPIN tissue blocks of
some of the PCa patients of this cohort) and 48 benignprostate tissues (BPT) (from the non-tumor blocks of some
of the cancer patients in this cohort).
Staining
Slide preparation and antigen retrieval were conducted as
previously described [14]. Briefly, the TMA slides were
taken through routine deparaffinization and rehydration,
pretreated with endogenous peroxidase block and retrieval
buffer. Slides were then rinsed with dH2O, then Tris
Buffered Saline (TBS), then TBS with Tween (TBST),
followed by protein blocking at room temperature.
E-cadherin antibodies (Cell Signaling Technology, Beverly,
MA) were used to define the epithelial compartment for
better tissue segmentation. Slides were then stained with
antibodies against HP1γ (EMD Millipore, Bilerica, MA)
[15] and Ki-67 (Abcam, Cambridge, MA).
Image analysis
For automated image acquisition and analysis, the
stained slides were loaded onto the slide scanner. Slides
were scanned as previously described [14]. Cores with
<5% epithelial component or loss of tissue were ex-
cluded from the analysis. Nuance system and inForm
1.2™ software (Caliper Life Sciences, Hopkinton, MA)
were used to for building spectral libraries on a per-cell
basis for HP1γ and Ki-67 target signals according to
manufacturer’s protocols. This system allows automated
quantitation of fluorescent staining on a per-cell basis
and selection of cellular subsets (nucleus versus cyto-
plasmic) for analysis of target signals.
Statistical analysis
Nuclear and cytoplasmic expression of individual cores of
various prostate tissues (benign, HGPIN, PCa, metastatic
PCa) was statistically compared using the t-test. Correlation
analysis was used to assess the relationship between HP1γ
and Ki-67 expression in each compartment. We then
assessed the relationship between HP1γ expression and pa-
tient clinicopathologic features using t-tests and analysis of
variance (ANOVA). For this analysis, multiple PCa cores
obtained from the same patient were first averaged, provid-
ing a more precise estimation of core expression in each
biological replicate. HP1γ expression was then compared
with clinicopathologic information (PSA, Gleason, pT stage,
tumor volume, SV involvement, margins, extracapsular ex-
tension, and evidence of metastasis) collected from the 64
patients included in this study. Univariate and multivariate
Cox regression analyses were used to assess whether nuclear
and cytoplasmic HP1γ (as continuous variables) predicted
biochemical recurrence following prostatectomy. Statistically
significant variables from univariate Cox analysis were then
entered into a multivariate Cox regression model. Variables
that were not independent predictors of recurrence were re-
moved using backward selection (P < 0.05). SPSS Version
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tical analyses. All tests were two-tailed and a P value < 0.05
was considered statistically significant.
Results
HP1γ expression in prostate core samples is elevated
in PCa, HGPIN, and metastatic PCa
We measured HP1γ expression on TMAs using
VECTRA™ quantitative immunofluorescent analysis. Ex-
pression was measured in both the nuclear and cytoplas-
mic compartments of epithelial and stromal cells. In
normal prostate tissues, HP1γ was expressed at low
levels. Total expression of HP1γ was significantly in-
creased in HGPIN and PCa, and was highest in meta-
static tumors compared to benign samples (Figure 1). In
the epithelial compartment, total, nuclear, and cytoplas-
mic expression were increased in PCa specimens com-
pared to benign (Figure 2A-C) (P-values <0.0001).
Nuclear levels of HP1γ were 2–3 fold higher than cyto-
plasmic staining for all benign and cancer samples.
To define overexpression, ROC curve analysis was
performed using total HP1γ expression to identify the
optimum cut point that maximized the sum of the sensi-
tivity and specificity for discriminating between benign
versus cancer cores. ROC analysis demonstrated excellentBenignA B
Cancer (Gleason 3+3=6)C D
Figure 1 HP1γ expression in human prostate cancer is increased com
cores) containing benign (A and B), HGPIN, low grade (C), high grade (D) a
cadherin (green) labels epithelial cells and DAPI (blue) the cell nuclei. Incre
than cytoplasmic. Low levels of HP1γ expression were infrequently observe
upregulated in the majority of prostate cancer cells.discrimination between benign versus cancer (AUC =
0.796, P < 0.0001) with a sensitivity and specificity of
76.2% and 73.5%, respectively (Figure 2D). Using the
optimum cut-off of 9.095 to define overexpression, 109/
143 (76.2%) of localized PCa cores, 40/50 (80%) of HGPIN
cores, and 40/41 (97.6%) of metastatic PCa cores demon-
strated overexpression of total HP1γ compared to only
23/88 (26.1%) of benign cores.
Ki-67 expression correlates with increased HP1γ expression
in PCa
Ki-67 is a known marker of cell proliferation that has been
demonstrated to complex with HP1γ on heterochromatin
[13,16,17]. We assessed the correlation between HP1γ and
Ki-67 on a per core basis. Within nuclear and cytoplasmic
compartments there was a significant correlation between
nuclear Ki-67 and HP1γ expression (Figure 3A-C). The
strength of the correlation was stronger for cytoplasmic
than nuclear expression (Pearson Coefficients 0.562 and
0.321, respectively, P <0.0001).
HP1γ expression is associated with Gleason score and pT
category
A series of clinicopathologic patient variables including
seminal vesicle involvement, tumor volume, GleasonBenign
Cancer (Gleason 4+4=8)
pared to benign normal prostate tissue. Tissue microarrays (336
nd metastatic PCa were immunoflourescently stained for HP1γ (red). E-
ased staining is noted in PCa samples with nuclear expression greater
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Figure 2 Quantitative analysis of HP1γ expression in human prostate cancer. VECTRA™ technology was used for automated image
attainment and analysis per the manufacturer’s protocol. Both the nuclear and cytoplasmic compartments were compared. Cell intensities were
averaged on a per cell basis for each core to determine the mean intensity of nuclear, cytoplasmic and total HP1y expression. Mean intensity of
expression of HP1y was then compared for benign, HGPIN, cancer and metastasis core samples with 95% confidence intervals. HP1y expression in
HGPIN, cancer (N= 146 cores), and metastasis is significantly greater than benign (N=96 cores) for total (A), nuclear (B), and cytoplasmic (C)
expression with P values <0.0001. Nuclear expression of the protein was ~2.5 fold greater than cytoplasmic expression. D) ROC curve analysis was
used to determine the optimum cut-off for defining overexpression. Total HP1γ expression demonstrated excellent discrimination between
benign and cancer (AUC = 0.796, P < 0.0001). A cut-off of 9.095 maximized the sensitivity (76.2) and specificity (73.5%) and was used to
define overexpression.
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capsular extension were compared to HP1γ nuclear and
cytoplasmic expression. Using HP1γ expression as a
continuous variable, we did not find an association of
the majority of these variables with HP1γ expression
(Table 1). However, the analysis did find that Gleason
score was associated with nuclear and total expression
(P = 0.018 and P = 0.042, respectively). In summary,
HP1γ expression does not appear to be tightly associated
with many standard clinicopathologic variables.
HP1γ expression predicts PSA recurrence
Univariate Cox survival analysis demonstrated that
Gleason score, stage (pT), seminal vesicle involvement,
metastasis, and cytoplasmic HP1γ expression predicted
biochemical recurrence (P < 0.05) (Table 2). Both nuclear
and cytoplasmic HPγ expression levels were analyzed as
continuous variables. Furthermore, using multivariate Coxregression, we demonstrated that only the presence of me-
tastasis and cytoplasmic HPγ were independent predictors
of biochemical recurrence following prostatectomy (P =
0.014 and P = 0.038, respectively) (Table 3). Gleason score
was no longer a statistically significant predictor of bio-
chemical recurrence on multivariate analysis (P > 0.05).
To verify that cytoplasmic Hp1γ was a strong predictor of
recurrence than Gleason score, we performed a Kaplan
Meier analysis of Gleason score alone (Figure 4A) versus
each Gleason score stratified by high versus low cytoplas-
mic HP1γ expression (Figure 4B). Use of HP1γ allowed
excellent separation of Gleason 7 patients into high (65%)
versus low (15%) probability of biochemical recurrence.
Furthermore, high HP1γ expression correctly predicted
recurrence in 10/11 (91%) of patients. However, with the
Gleason system, having high-grade disease (Gleason 8 or
9) was only able to correctly identify 6/12 (50%) cases of
recurrence.
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P < 0.0001
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Figure 3 HP1γ expression correlates with Ki-67. VECTRA™ technology was used for automated image attainment and analysis per the
manufacturer’s protocol to assess immunoflourescent staining of Ki-67 and HP1γ. Pearson correlation coefficients yielded significant relationships between
mean intensity expression of nuclear Ki-67 and A) total ( P = 0.34), B) nuclear ( P = 0.32), and C) cytoplasmic ( P = 0.562) HP1γ. All P values <0.0001.
Slezak et al. BMC Cancer 2013, 13:148 Page 5 of 8
http://www.biomedcentral.com/1471-2407/13/148Discussion
Patients and clinicians are in need of more accurate bio-
markers to predict the prognosis of prostate cancer, es-
pecially for intermediate grade tumors [18]. Few markers
have been reported that reliably predict treatment failure
(e.g. PSA recurrence after surgery). Altered nuclear
shape and size are a hallmark of cancer and reflect
changes in chromatin structure. Image analyses of het-
erochromatin content and nuclear shape have been
reported to improve the prediction of PCa prognoses
[19]. HP1γ is a member of the HPI family of proteins in-
volved in chromatin packaging and gene regulation. The
current study represents the first in depth analysis of
HP1γ expression for any cancer. We observe an increase
in HP1γ expression in the majority of prostate cancers.
Furthermore, by analyzing staining in distinct cellular
compartments in a cohort of patients with extended
follow-up, we find a role for the expression of this gene
in predicting treatment failure.
A unique strength of this study lies in our use of the
newly validated VECTRA™ imaging technology. The
platform merges automated slide scanning, multi-
spectral imaging technology, and pattern recognition
software into a system for biomarker analysis. VECTRA™
has many advantages over other imaging systems forbiomarker quantitation [14]. VECTRA™ allows re-
searchers to objectively analyze expression within separ-
ate epithelial and stromal tissue compartments. Nuclear
and cytoplasmic staining within these compartments is
concurrently assessed and multiple markers may be
addressed simultaneously. The system is highly auto-
mated and uses pattern recognition to measure expres-
sion on a per-cell, core, or compartment basis on TMAs.
The algorithm designed to segment tissue compartments
by our genitourinary pathologist [WH] had a 97% rate of
acceptable tissue segmentation. In the current analysis,
VECTRA™ permitted a reproducible assessment of
HP1γ, and its association with Ki-67, in multiple cell
compartments for a large cohort of patients.
HP1γ and the other HP1 family members have been
primarily studied during embryogenesis and develop-
ment, including that of the prostate [4]. Expression of
HP1γ was noted in the fetal prostate at 14 and 24 weeks
of gestation. This is in contrast to HP1α which is not
expressed at those developmental stages [4]. Decreased
expression of HP1γ is required for normal cellular differ-
entiation [5,6]. Our study demonstrates that expression
of HP1γ occurs in 98% of metastatic and 76% of local-
ized PCa tumors compared to 26% of benign tissues.
This cut-off was determined by ROC analysis to
Table 1 Association of Hp1γ expression with patient pathological features
Variable Number
Nucleus Cytoplasm Total
Mean intensity (SD) p-value Mean intensity (SD) p-value Mean intensity (SD) p-value
Gleason
3+3 or 3+4 47 8.77 (2.5) 0.018 3.02 (0.8) 0.095 11.8 (3.2) 0.042
4+3 or 4+4 or 4+5 12 10.74 (2.5) 4.1 (2.0) 14.9 (4.5)
Stage
T2 40 8.62 (2.7) 0.238 2.86 (0.9) 0.039 11.48 (3.4) 0.12
T3 12 9.46 (1.6) 3.47 (0.7) 12.92 (2.2)
T4 11 10.0 (2.9) 3.77 (2.0) 13.78 (4.7)
Tumor Volume
<5 7 9.59 (1.8) 0.776 3.07 (0.8) 0.156 12.67 (2.4) 0.879
5-20 36 8.84 (2.9) 3.06 (1.4) 11.91 (4.0)
>20 20 9.09 (2.4) 4.01 (2.5) 12.03 (3.1)
SV involvement
No 49 8.96 (2.6) 0.684 3.04 (1.2) 0.182 12.01 (3.7) 0.468
Yes 11 9.30 (2.5) 4.76 (3.0) 12.29 (3.3)
Margins Positive
No 41 9.40 (2.6) 0.105 3.22 (1.3) 0.469 12.55 (3.7) 0.876
Yes 21 8.25 (2.5) 3.0 (1.0) 11.25 (3.4)
Extracapsular
No 46 8.91 (2.8) 0.633 3.39 (2.0) 0.875 11.83 (3.8) 0.471
Yes 17 9.26 (2.0) 3.31 (0.9) 12.57 (2.8)
Metastasis
No 52 8.95 (2.7) 0.723 3.11 (1.2) 0.640 12.07 (3.7) 0.682
Yes 12 9.25 (2.04) 4.50 (3.1) 11.97 (2.7)
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benign versus cancer. Adjusting this cut point for Hp1-
gamma overexpression can increase the sensitivity or
specificity depending on its required use. Total expression
was associated with higher Gleason score (p = 0.04).
One notable finding was that HP1γ was not only an
independent predictor of PSA-recurrence for patientsTable 2 Univariate cox regression analysis for predicting bioc
Variables* Coefficent s.e.
Gleason category 0.392 0.197
Stage (pT) category 0.860 0.355
Tumor volume 0.051 0.298
Seminal vesicle involvement 1.195 0.542
Margins −0.154 0.574
Extracapsular extension 0.792 0.513
Metastasis 1.414 0.516
Nuclear Hp1γ (continuous) 0.043 0.107
Cytoplasmic Hp1γ (continuous) 0.751 0.356who underwent radical prostatectomy, but was superior
to pathological Gleason score using both a multivariate
Cox model and a Kaplan-Meier analysis (Table 3 and
Figure 4). Few biomarkers to date are able to predict
PSA recurrence more robustly than Gleason score. Re-
cently, Cuzick et al. reported a panel of 31 RNA markers
had a more significant P value compared to Gleasonhemical recurrence
Wald P Odd ratio (95% CI)
4.025 0.045 1.485 (1.009-2.186)
5.853 0.016 2.363 (1.177-4.741)
0.029 0.864 1.052 (0.587-1.887)
4.860 0.027 3.305 (1.142-9.566)
0.072 0.789 0.858 (0.278-2.641)
2.386 0.122 2.208 (0.808-6.033)
7.489 0.006 4.112 (1.495-11.312)
0.165 0.685 1.044 (0.847-1.287)
4.449 0.035 2.118 (1.055-4.255)
Table 3 Multivariate cox regression analysis for predicting biochemical recurrence
Variables* Coefficent s.e. Wald P Odd ratio (95% CI)
Remained in model: (P < 0.05):
Metastasis 1.690 0.690 6.005 0.014 5.418 (1.402-20.930)
Cytoplasmic Hp1γ (continuous) 0.899 0.432 4.320 0.038 2.456 (1.053-5.732)
*Variables removed from the model (P > 0.05): Gleason category, stage (pT) category, seminal vesicle involvement.
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ation for the robustness of HP1γ is that its prognostic
value is not collinearly associated with other clinicopath-
ologic variables (Table 1). Given the role HP1γ plays in
gene repression [3,21] and development [4], we postulate
that aberrant expression of this protein may be central
to the pathophysiology of PCa.
Increased expression of HP1γ in the nucleus compared
to the cytoplasm is consistent with data demonstrating
this protein is primarily localized to centromeric and
telomeric heterochromatin [3,8] and euchromatin
[22,23]. It was of interest to find expression of the pro-
tein in the cytoplasm and note that this carried prognos-
tic significance. Its presence in the cytoplasm may
represent altered protein processing, or may have some
as of yet unknown functional significance. Ki-67 is a nu-
clear protein that correlates with cell proliferation and is
a known marker of PCa progression [24]. The C-
terminal domain has been found to bind to all three
members of the HP1 family [13]. We found a significant











Log rank P = 0.201
Figure 4 Kaplan Meier analysis comparing pathological Gleason score
in samples stained for Hp1γ. A) Gleason score provides minimal separation
rank analysis (P = 0.2). B) Cytoplasmic Hp1γ is superior to pathological Glea
Hp1γ. The median value for Hp1γ staining in was 3.5 in all benign and can
define high versus low cytoplasmic Hp1γ expression for the Log rank analy
Gleason category including intermediate grade cancer (GS 6, 7).(Figure 2). Given the more uniform expression of HP1γ
across prostate cancer cells when compared to Ki-67, it
clearly has other functions independent from Ki-67 in
the regulation of heterochromatin.
Conclusion
In conclusion, we demonstrate that HP1γ expression
is elevated in PCa and this independently predicts
PSA-recurrence for patients more accurately than patho-
logical Gleason score. Use of novel biomarkers to iden-
tify men at lower risk for recurrence may reduce the
need for unnecessary adjuvant radiation therapy. HP1γ
represents a novel marker of prostate cancer progression
that will be useful to the clinician with further validation
in other datasets. In addition, examination of HP1γ ex-
pression in biopsy specimens might fulfill an urgent
need for more accurate pre-treatment risk stratification
tools. Given the role HP1γ plays in epigenetic gene regu-
lation through its binding to methylated lysine on his-
tone H3 (H3K9me) [7], it represents a novel target for














versus Hp1γ. PSA failure after radical prostatectomy was examined
of patients into risk categories for biochemical recurrence using a Log
son score when Gleason score was stratified into high versus low
cer samples and this value was subsequently used as a cut point to
sis. Hp1γ accurately predict biochemical recurrence within each
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http://www.biomedcentral.com/1471-2407/13/148tumors suggests HP1γ may be overexpressed in other
epithelial cancers [3].
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